6 February 2024 in Nature Communications
Immunotherapy with immune checkpoint blockade (ICB) for glioblastoma (GBM) is promising but its clinical efficacy is seriously challenged by the blood-tumor barrier (BTB) and immunosuppressive tumor microenvironment. Here, anti-programmed death-ligand 1 antibodies (aPD-L1) are loaded into a redox-responsive micelle and the ICB efficacy is further amplified by paclitaxel (PTX)-induced immunogenic cell death (ICD) via a co-encapsulation approach for the reinvigoration of local anti-GBM immune responses. Consequently, the micelles cross the BTB and are retained in the reductive tumor microenvironment without altering the bioactivity of aPD-L1. The ICB efficacy is enhanced by the aPD-L1 and PTX combination with suppression of primary and recurrent GBM, accumulation of cytotoxic T lymphocytes, and induction of long-lasting immunological memory in the orthotopic GBM-bearing mice. The co-encapsulation approach facilitating efficient antibody delivery and combining with chemotherapeutic agent-induced ICD demonstrate that the chemo-immunotherapy might reprogram local immunity to empower immunotherapy against GBM.
17 March 2026 in Nature Communications
Immunosuppressive myeloid cells, including immature dendritic cells (DC) and tumor-promoting macrophages, drive tumor progression and immune evasion. Reprogramming these cells into immune effectors remains challenging. Here, we present a programmable nanomicelle platform that reconfigures myeloid immunity to combat both primary and metastatic breast cancer (BC). The nanomicelles co-deliver photosensitizers (IR825), anti-PD-L1 antibodies, and antagomiR-182 with spatiotemporal precision. Upon activation, they induce immunogenic cell death, promoting DC maturation to enhance antigen presentation. Concurrently, miR-182 inhibition repolarizes M2-like macrophages into M1-like phenotypes via the TLR4/MYD88/NF-κB pathway. This dual reprogramming enhances CD8+ T cell infiltration and functionality, driving durable anti-tumor responses. In multiple BC models, the platform suppresses tumor growth, prevents metastasis, and induces long-term immune memory. Its efficacy and immunomodulatory effects were further validated in a patient-derived tumor fragment assay and patient-derived xenograft models, highlighting translational potential. This work offers a clinically relevant strategy to rewire tumor-promoting myeloid cells for cancer immunotherapy.